Figure 1From: Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study Cumulative proportion survival without deterioration in glucose tolerance according to baseline plasma asymmetric dimethylarginine (ADMA). Back to article page